Drug Profile
INO 3107
Alternative Names: INO-3106; INO-3107Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Inovio Pharmaceuticals; University of Pennsylvania
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Recurrent respiratory papillomatosis
- No development reported Head and neck cancer; Human papillomavirus infections; Lung cancer
Most Recent Events
- 03 Jan 2024 INOVIO Pharmaceuticals plans to submit BLA in Recurrent Respiratory Papillomatosis via FDA's accelerated approval program in the second half of 2024
- 03 Jan 2024 INOVIO plans to launch INO 3107 in 2025
- 13 Oct 2023 Inovio Pharmaceuticals receives feedback from the US FDA that data from completed phase I/II trial could support the submission of BLA for Recurrent respiratory papillomatosis